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Abstract: Cutaneous squamous cell carcinoma (SCC) is the second most common human skin cancer with
a rapidly increasing incidence among the Caucasian population. Among the many regulators, responsible
for cancer progression and growth, microRNAs (miRNA) are generally accepted as key players by now.
In our current study we found that microRNA-181a (miR-181a) shows low abundance in SCC compared
to normal epidermal skin. In vitro, miRNA downregulation in normal primary keratinocytes induced
increased proliferation, while in vivo miR-181a downregulation in HaCaT normal keratinocytes showed
tumor-like growth increase up to 50%. Inversely, upregulation of these miRNAs in cancer cells lead
to reduced cellular proliferation and induction of apoptosis in vitro. An in vivo therapeutic model
with induced miR-181a expression in SCC13 cancer cells reduced tumor formation in mice by 80%.
Modulation of miR-181a levels showed an inverse correlation with the proto-oncogene KRAS both on
mRNA and protein level by direct interaction. Knockdown of KRAS mimicked the anti-proliferative
effects of miR-181a overexpression in patient-derived SCC cells and abolished the enhanced viability of
HaCaT cells following miR-181a knockdown. Furthermore, phospho-ERK levels correlated with KRAS
levels, suggesting that the observed effects were mediated via the MAPK signaling pathway. miR-181a
seemed regulated during keratinocyte differentiation probably in order to amplify the tumor suppressive
character of differentiation. Taken together, miR-181a plays a crucial tumor suppressive role in SCC by
targeting KRAS and could be a promising candidate for a miRNA based therapy.
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Abstract
Cutaneous squamous cell carcinoma (SCC) is the second most common human skin can-
cer with a rapidly increasing incidence among the Caucasian population. Among the many
regulators, responsible for cancer progression and growth, microRNAs (miRNA) are gener-
ally accepted as key players by now. In our current study we found that microRNA-181a
(miR-181a) shows low abundance in SCC compared to normal epidermal skin. In vitro,
miRNA downregulation in normal primary keratinocytes induced increased proliferation,
while in vivo miR-181a downregulation in HaCaT normal keratinocytes showed tumor-like
growth increase up to 50%. Inversely, upregulation of these miRNAs in cancer cells lead to
reduced cellular proliferation and induction of apoptosis in vitro. An in vivo therapeutic
model with induced miR-181a expression in SCC13 cancer cells reduced tumor forma-
tion in mice by 80%. Modulation of miR-181a levels showed an inverse correlation with
the proto-oncogene KRAS both on mRNA and protein level by direct interaction. Knock-
down of KRAS mimicked the anti-proliferative effects of miR-181a overexpression in
patient-derived SCC cells and abolished the enhanced viability of HaCaT cells following
miR-181a knockdown. Furthermore, phospho-ERK levels correlated with KRAS levels,
suggesting that the observed effects were mediated via the MAPK signaling pathway.
miR-181a seemed regulated during keratinocyte differentiation probably in order to
amplify the tumor suppressive character of differentiation. Taken together, miR-181a
plays a crucial tumor suppressive role in SCC by targeting KRAS and could be a promis-
ing candidate for a miRNA based therapy.
Introduction
Cutaneous squamous cell carcinoma (SCC) is the second most common skin malignancy in
the general population with a rapidly rising incidence among Caucasians. It typically arises
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from intraepithelial lesions like actinic keratosis on sun-damaged skin [1, 2]. Disturbed differ-
entiation represents a hallmark of SCC reflected by a diverse pattern of differentiation markers
like Filaggrin and Involucrin or various keratins [3]. About 50% of all SCCs carry p53 muta-
tions and a typical UV signature presenting with cyclobutane pyrimidine dimers, making UV
light a major SCC risk factor [4]. Organ transplant recipients (OTR), however, harbor a 65–
250 fold increased SCC incidence compared to the general population due to continued
immunosuppression [5]. Once SCC occurs, further SCC arising on sun-damaged skin are
likely. Field-directed treatments like photodynamic therapy, imiquimod or ingenol mebutate
are available, but all cause considerable inflammation and disfiguration [6, 7]. Here, future
siRNA or microRNA based agents could prove beneficial by reverting a keratinocyte’s course
towards regular differentiation and cell death without inflammation.
miRNAs are approximately 20 nucleotide-long non-coding RNA molecules binding to the
3’ untranslated regions (UTR) of target mRNAs in a sequence-specific manner influencing
translation and/or stability of the transcripts [8]. miRNA effectively play roles in almost all
aspects of cancer biology, such as in proliferation, apoptosis, metastasis and angiogenesis
(reviewed in [9]). A large screen of miRNA expression in SCC singled out miR-181a as down-
regulated in our SCC patient samples. We thus studied expression and functionality of miR-
181a in primary patient-derived and various cell lines representing normal skin and SCC. Our
findings indicate a crucial role for miR-181a in regulating keratinocyte proliferation mediated
by KRAS interaction and MEK pathway inhibition, prompting us to validate these findings in
a xenograft mouse model.
Materials and methods
Cell culture
HaCaT, SCC13 and HEK293T [10–12] were cultured in DMEM high-glucose supplemented
with 10% FCS (Gibco). Gibco’s SMF Keratinocyte medium, supplemented with EGF and
Bovine Pituitary Extract (BPE), was used for SCC12 [11]. Primary patient-derived cells were
grown in CnT-07 medium (CellNTec). Several cells were cultivated in a humidified 5% CO2
atmosphere at 37˚C.
Institutional board approval for the use of human tissue was granted by the local IRB (Kan-
ton of Zu¨rich); all donors signed written informed consent forms in accordance with the Code
of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involv-
ing humans (ethical approval number EK647 and EK800). All samples were obtained from the
University Hospital Zurich (Zurich, Switzerland).
Viability and proliferation assays
2000–3000 treated cells/well were seeded into 96 well plates in the according growth medium.
After 96 hours’ incubation the medium was swapped with fresh one containing 1:10 WST-1
(Roche) and 10% FCS. WST-1 assay was performed following the manufacturer’s protocol.
Proliferation was assessed by bromodeoxyuridine (BrdU) incorporation using a BrdU assay
Kit (Merck Millipore).
RNA isolation and qPCR
RNA was isolated form pelleted cells or tissue samples using TRIzol (Invitrogen) following the
manufacturer’s protocol. Promega’s Reverse Transcription System was used to transcribe
mRNA samples into (poly T-) cDNA.
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Gene expression analyses of coding genes (i.e. long transcripts) was performed using SYBR
Green (Roche) while short transcripts (i.e. miRNAs) were analyzed using LifeTechnologies’
TaqMan microRNA Assays and small nuclear RNA Z30 as a housekeeping gene. All assays
were performed according to the manufacturer’s protocols and quantified using ddCT method.
Primer sequences for SYBR green qPCR: 36B4 (housekeeping gene) forward: 3’—GCAAT
GTTGCCAGTGTCT—5’ reverse: 3’—GCCTTGACCTTTTCAGCA—5’, HRAS forward: 3’—GA
CGTGCCTGTTGGACATC-5’ reverse: 3’–CTTCACCCGTTTGATCTGCTC—5’, KRAS for-
ward: 3’—AAGACAGAGAGTGGAGGATGC—5’ reverse: 3’—GTGCTGAACTTAAACTTACCAG
AT—5’, RhoA forward: 3’–GGAAAGCAGGTAGAGTTGGCT—5’ reverse: 3’—GGCTGTCGATG
GAAAAACACAT—5’, pIND20 Notch1: forward: 3’—CCGCTACTCACGCTCTGA—5’ reverse:
3’—CTGGAAGACACCTTGTGC—5’, Involucrin: forward: 3’—TCCTCCAGTCAATACCCA—5’
reverse: 3’—CAGCAGTCATGTGCTTTT—5’, Filaggrin: forward: 3’—TGAAGCCTATGACAC
CAC—5’ reverse: 3’—TCCCCTACGCTTTCTTGT—5’, Loricrin: forward: 3’—GCGAAGGAGTT
GGAG—5’ reverse: 3’—CTGGGTTGGGAGGTACT—5’:Keratin 10: forward: 3’—GGTGGGAGT
TATGGAGGCAG—5’ reverse: 3’—CGAACTTTGTCCAAGTAGGAAGC—5’
Protein detection
Cells were washed with PBS and lysed in RIPA buffer (Cell Signaling Technology, #9806).
Protein extracts were analyzed by Western blotting using antibodies: anti-pp42/44 (#9101),
anti-p42/44 (#9102), anti-rabbitHRP (#7074) all from Cell Signaling Technology. Anti-KRAS
(sc-30) anti-Filaggrin (sc-66192), anti-Involucrin (sc-21748), anti-Loricrin (sc-51130), anti-b-
actin (sc-47778) from Santa Cruz Biotechnology and anti-RhoA (ab187027) from abcam.
Anti-mouse IgG (926–68022 and 925–32212) anti-rabbit IgG (926–68023 and 925–32213) and
anti-goat IgG (926–68024 and 925–32214) all from LI-COR. Rabbit anti-mouse IgG H&L
HRP (ab6728). Proteins were detected by ECL on Hyperfilm (Amersham, GE Healthcare) or
by LI-COR Odyssey Infrared scanning system.
Flow cytometry
SCC13 cells, transfected with miR-181a mimics, were stained using BD Pharmigen’s FITC
Annexin V Apoptosis Detection Kit I following the manufacturer’s protocol. UVB-irradiated cells
were used as a positive control and to adjust proper gate setup. Measurements were performed on
a FACSCanto device (BD Biosciences). Data were analyzed with FlowJo software (Ashland).
Transfection
Transient transfection of siRNAs (Qiagen), miRNA mimics, miRNA inhibitors and according
control sequences (Abcam) was performed using Interferin (Polyplus). Larger constructs, like
DNA plasmids, were transfected by the aid of GeneCarrier 1 (Epoch Biolabs). All transfections
were carried out for 48 hours and following the manufacturer’s protocol. In short, cells were
seeded 24 hours prior to transfection followed by medium change. The according transfection
reagent was diluted in basal medium after nucleotides were added. After 30 minutes of incuba-
tion the solution was added drop wise to the cells and incubated at 37˚C for 48 hours.
siRNA sequences: control sequence: 5’–AATTCTCCGAACGTGTCACGT–3’, siKRAS_7:
5’–CTCCTAATTATTGTAATGTAA–3’, siKRAS_8: 5’–AAGGAGAATTTAATAAAGATA–3’.
Transduction
Lentiviral particles were either obtained by Sigma Aldrich (MISSION1 Lenti microRNA
Inhibitors, MISSION1 Lenti microRNA and the according control constructs) or produced
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using the psPAX2 Second Generation System in HEK293T cells. A detailed protocol for lenti-
viral particle production can be found in Barde et al [13]. In short, psPAX2 plasmids and the
construct of interest were co-transfected into HEK293T cells using GeneCarrier-1 (Epoch Bio-
labs) for 24 hours, followed by daily medium change for 3 days in total. All supernatants were
collected and pelleted in an ultra-centrifuge. Pellets were resuspended in DMEM 10% FCS and
stored at -80˚C. SCC13 cells were seeded 24 hours prior to the experiment. For the transduc-
tion, medium was swapped with DMEM 10% FCS containing 8μg/ml of hexadimethrine bro-
mide (Sigma) and resuspended lentiviral particles overnight. The next day, medium was
swapped with regular DMEM 10% FCS. After another 24 hours, the selection process was initi-
ated using puromycin (Santa Cruz Biotechnology). Remaining cell clones were expanded and
tested for functionality.
In vivo tumor xenograft
Female nude mice (4–6 weeks old) were ordered from Harlan Laboratories Inc. All experi-
ments were performed according to guidelines of the approved BLV protocol (Bew 104/2013,
approved by the veterinary office of the Kanton Zu¨rich). Furthermore, the veterinary office of
the Kanton Zu¨rich specifically approved the present study as an extension to our current
license (license number: 24156).
4 × 106 HaCaT kd miR-181a, 1 × 106 of SCC13 Tet-On miR-181a, or the according number
of control cells were suspended in PBS and injected subcutaneously after mice accommodated
to their new habitat for 10–14 days. 10 animals per group were used for experiments involving
HaCaT cells and 15 animals per group were used for in vivo SCC13 experiments. Doxycycline
for the Tet-On experiment was administered via food pellets (200mg/kg) (Bioserv). The
tumors were measured using a caliper three times a week. The tumor volume was calculated
using the formula volume, V = L × W2/2, where L represents long diameter and W stands for
short diameter. In parallel, mice where weighted once per week using a standard laboratory
scale. Mice were euthanatized in case one or more termination criteria were fulfilled, such as
tumor mass greater than 1cm3, ulcerating tumors, severe weight loss or lack of fight/flee
instincts or at the experiment’s endpoint using CO2. Tumors of dead mice were bisected,
whereat RNA was isolated from one half and Hematoxylin-eosin (H&E) slides were produced
from the other part.
Histology
Excised tumor from terminated mice were fixed in 4% formalin, followed by dehydration and
embedding in paraffin. Seven micron sections were cut and stained with hematoxylin and
eosin staining (H&E).
Construction of Tet-On miRNA over expression plasmids
miR-181a hair pin sequence plus 210 base pairs of the flanking region in either direction and
the according Gibson Assembly adapters were synthesized (Integrated DNA Technologies).
The inserts were cloned into digested pTRIPZ (EcoRI and XhoI) using NEB’s Gibson Assem-
bly kit following the manufacturer’s protocol. Empty pTRIPZ constructs served as an internal
control.
Generation of cell lines stably overexpressing KRAS
pUNO KRAS over expression plasmid (Invivogen) was transfected into cell lines as described
above. Positive cells were selected using Blasticidin (5μM) (Invivogen). Clones were picked,
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expanded and checked for stable KRAS expression. For KRAS 3’UTR experiments pGL4.75-
KRAS LCS6m (Addgene Plasmid #44571) was used as a KRAS 3’UTR donor and sub cloned
into pUNO KRAS with NheI-HF and T4 DNA ligase (NEB). Three miR-181a sites were
mutated using Phusion-HF polymerase for mutagenesis (NEB) and the following primers:
First site: forward: 5’—CTTCTTATTTTTCTTACCAATTGTTCCGGTTGGTGTGAAACAAATT
AATGAAGC—3’ reverse: 5’—GCTTCATTAATTTGTTTCACACCAACCGGAACAATTGGTAA
GAAAAATAAGAAG—3’, second site: forward:
5’—GTCCTATAGTTTGTCATCCCTGATTCCGGTAAAGTTACACTGTTCACAAAGGTTTT
GTC—3’ reverse: 5’—GACAAAACCTTTGTGAACAGTGTAACTTTACCGGAATCAGGGATGA
CAAACTATAGGAC—3’, third site: forward: 5’—CGTATATTGTATCATTTGAGTTCCGGTTCC
CAAGTAGGCATTCTAGGC—3’reverse: 5’—GCCTAGAATGCCTACTTGGGAACCGGAACTCA
AATGATACAATATACG—3’.
The pUNO1 control plasmid (Invivogen) was used as a negative control during functional
experiments
MEK inhibitor
For MEK inhibition GSK1120212 (Cellagen Technology, #C4112-5) was used at concentra-
tions of 500 nmol/L. DMSO (Sigma) was used to prepare stock solutions and also as a control
treatment during the experiments.
Ras family mutation analysis of cell lines
Mutation analysis of KRAS, NRAS and HRAS were performed strictly following the protocol
by Chang and colleagues [14] 19879255. In short, genomic DNA from cell lines was isolated
and purified using Qiagen’s DNA isolation kit (Cat No./ID: 51104). Regions of interest were
PCR amplified followed by a gel purification step. Sanger sequencing was outsourced to
Microsynth AG.
Statistics
All statistical evaluations were carried out using GraphPad Prism 5.0. The analyses were two-
tailed Student’s t-Test of three independent experiments. The error bars represent standard
deviations (SD). In vivo experiments were evaluated using ANOVA with Bonferroni correc-
tion where error bars represent standard error of the mean (SEM). p-values of< 0.05 were
considered significant.
Results
miR-181a is downregulated in SCC compared to normal skin
In order to get a general overview into the miRNA landscape in SCC we extracted total RNA
of the epidermal fraction of SCC from patients (n = 15) as well as normal skin control samples
(n = 5).
The initial microRNA microarray screen revealed a highly deregulated miRNA pattern of
the two SCC groups when compared to normal skin. miR-181a showed low abundance among
SCC confirmed by TaqMan qPCR (Fig 1A).
Low levels of miR-181a result in increased cellular viability in vivo and in
vitro
Decreased cellular presence of miRNAs presumably permits increased activity of their down-
stream targets and might in turn promote tumor formation. For the following functional
miR-181a in cutaneous squamous cell carcinoma
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assays, we set up a keratinocyte culture system from patient-derived SCC and normal cutane-
ous primary keratinocytes. In addition, we selected a panel of keratinocyte cell lines according
to their basal miRNA expression levels (S1 Fig). Since HaCaT, a cell line derived from normal
human keratinocytes, and human SCC cell lines SCC13 and A431 exhibit miR-181a levels sim-
ilar to patient samples, these cell lines were considered most suitable for our experiments.
With regard to subsequent functional assays we performed genotyping of H-, K-, and NRAS
codons 12, 13, and 61 mutations in the HaCaT and SCC-13 cell lines. With the exemption of a
heterozygous HRAS G12N mutation in the SCC-13 cell line, the two cell lines did not harbor
genetic alterations in the sequenced regions (S2 Fig).
Indeed, HaCaT cells harboring a stable miR-181a knockdown (kd miR-181a) and injected
subcutaneously into nude mice had pronounced cyst formation capability while the respective
control cells hardly formed a cyst (Fig 1B and S4A and S4B Fig). H&E histological sections of
the kd miR-181a cysts did not only differ in size, but revealed pathological characteristics typi-
cal for intraepithelial SCC: Disturbed differentiation with distinct eosinophilic hyperkeratosis
accompanied by parakeratosis akin to human SCC. Control cysts, on the other hand, showed
relatively inconspicuous keratinocyte differentiation and basophilic cornification (Fig 1C). In
vitro WST-1 assays confirmed the inverse correlation between cellular viability and miR-181a
levels; kd miR-181a showed greater values compared to control cells (Fig 1D). HaCaT kd miR-
181a cells isolated from cysts after the experiments endpoint or from in vitro cultures exhibited
lower miR-181a levels when compared to control cells (S4C Fig and S5 Fig). On the contrary,
knockdown of miR-181a did not induce proliferation in primary SCC cells or SCC13 in which
miR-181a was already lower, indicating that a 3-5-fold reduction in miR-181a was already suf-
ficient to confer the maximum induction of proliferation (Fig 1F).
Fig 1. Low abundance of miR-181a is found in patient derived SCC specimen compared to normal skin
and down regulation of miR-181a leads to increased viability in healthy keratinocytes. (A) Total RNA was
isolated from patient derived SCC or normal skin biopsies (epidermal part). miR-181a levels were determined via
TaqMan qPCR. (B) HaCaT knock down (kd) miR-181a or control cells were injected subcutaneously into nude
mice. Over all significance of the time course experiment was calculated using two way Anova and Bonferroni
correction. A Student’s t-Test was performed at the end point (day 24) (Figure B in S4 Fig). (C) H&E sections of
cysts. Black bar = 100μm. (D) Viability of HaCaT kd miR-181a cells in vitro. (E + F) Cells were transfected with
miR-181a inhibitors for 48 hours. For in vitro viability assays cells were seeded into 96 well plates and incubated
for 96 hours followed by WST-1 assay. P values for in vitro assays were Calculated via Student’s T test.
SCC = cultured SCC cells derived from patient samples, PK = cultured healthy keratinocytes derived from
patient samples.
https://doi.org/10.1371/journal.pone.0185028.g001
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Due to its simplicity combined with a high degree of sensitivity as well as reliability, WST-1
is widely used to investigate differences in cellular proliferation rates. We are well aware that
WST-1 is reduced in the mitochondria during events happening in the respiratory chain and
reflects therefore metabolic activity. To evaluate this assay for our needs, we performed a
WST-1 assay on healthy primary keratinocytes transfected with miR-181a or control inhibi-
tors. In parallel all cells were counted at the starting and end point of the assay and normalized
to control cells. In addition, we performed a BrdU incorporation assay, which represents
another widely used, but more complex proliferation assay. Since the WST-1 measurement,
manual cell counting and BrdU incorporation assay delivered comparable results, we con-
cluded that mitochondrial activity adequately reflects cellular proliferation rates in keratino-
cytes (S3 Fig). For the sake of correct scientific terminology however, we will stick to the term
“viability” in our graphs.
High levels of miR-181a result in decelerated cellular viability in vivo and
in vitro
Following our observation of an inverse correlation between miR-181a levels and cellular via-
bility, we were speculating that an upregulation of miR-181a would lead to decreased cellular
viability in cancer cells. Therefore, we established a tetracycline-inducible miR-181a over
expression model based on pTRIPZ Tet-On plasmid and SCC13 cells (Tet-On miR-181a).
When injected subcutaneously into nude mice, control cells formed rapidly growing tumors,
reaching termination criteria (tumor size > 1cm3 and/or ulceration) relatively early. miR-181a
over expressing cells, on the other hand, grew slower and reach termination criteria at later
time points (Fig 2A and Figures A-C in S6 Fig).
Fig 2. Up regulation of miR-181a leads to decreased viability in cancer cells. (A) SCC13 was transduced
with pTRIPZ for inducible miRNA overexpression (SCC13 Tet-ON miR-181a) and injected subcutaneously
into nude mice. Doxycycline (200 mg/kg) was administered via food pellets. Over all significance of the time
course experiment was calculated using two way Anova and Bonferroni correction. (B) SCC13 Tet-On miR-
181a were seeded into 96 well plates and exposed to doxycycline during the course of the experiment. Cells
were transduced with pLKO.miRNA (ki miR-181a) for stable miRNA overexpression (C) or transfected with
miRNA mimics for 48 hours (D + E). Cells were seeded into 96 well plates and incubated for 96 hours followed
by WST-1 viability assay. P values for in vitro assays were calculated via Student’s t-Test. SCC = cultured
SCC cells derived from patient samples, PK = cultured healthy keratinocytes derived from patient samples.
https://doi.org/10.1371/journal.pone.0185028.g002
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In addition, Tet-On miR-181a showed decreased viability when doxycycline was added to
the medium (Fig 2B). Maintained miR-181a expression in tumors with Tet-On miR-181a and
in vitro cell cultures confirmed a robust miRNA induction by doxycycline activation (S6D Fig
and S7A Fig). Fittingly, transfection of synthetic miRNAs (miRNA mimics) into cancer cells
or stable miR-181a knock in led to decreased cellular viability accompanied by cell rounding
and detachment (Fig 2D and Figure B in S8 Fig). FACS analyses as well as immunoblotting
revealed a high number of apoptotic cells, identified by AnnexinV+/7AAD- staining and Cas-
pase-3 cleavage respectively, compared to the control group transfected with control miRNA
(Figure A in S8 Fig). Interestingly, healthy primary keratinocytes and HaCaT cells were vul-
nerable to miR-181a upregulation to a certain degree as well (Fig 2E). An additional conforma-
tion was done in SCC13 cells transduced with a stable miR-181a over expression plasmid (ki
miR-181a). As expected, these cells exhibited lower viability compared to control cells, while
their miR-181a levels were strongly upregulated (Fig 2C and Figure B in S7 Fig).
KRAS is a direct target of miR-181a
Next we aimed to unravel the molecular mechanism laying behind miR-181a’s negative effect
on cellular viability. The proto-oncogene KRAS plays a critical role in a variety of malignancies
and the interplay of miR-181a and KRAS has been described in other epithelial cancers [15].
Healthy cells with repressed miR-181a, either by transfection of miRNA inhibitors (Fig 3A)
or by stable knock down (Fig 3B), showed higher KRAS protein and mRNA levels. SCC13
cells, on the other hand, exhibited lower KRAS levels when miR-181a was upregulated either
by transfection of miRNA mimics (Fig 3C) or by stable miR-181a over expression (Fig 3D).
miRNAs are interacting with the 3’UTRs of their target mRNAs in a sequence-specific man-
ner and are thereby interfering in the process of protein translation. In our approach we took
advantage of the KRAS overexpression plasmid pUNO KRAS and cloned the according 3’UTR
upstream of the start codon. A 3’UTR containing mutated miR-181a binding sites served as a
control (Fig 3E). HaCaT cells stably transfected with these plasmids were characterized by ele-
vated KRAS protein levels. However, only the cells containing the wild type KRAS 3’UTR were
vulnerable to miR-181a mimic transfection resulting in reduced KRAS protein translation and
thus in reduced cellular viability (Fig 3F). The same KRAS 3’UTR system transfected into
HEK293T cells showed a similar picture. Cells harboring the wild type KRAS ‘3UTR had
reduced KRAS protein after miR-181a mimics treatment while cells harboring a mutated
3’UTR were less responsive to miR-181a mimics (S9 Fig).
Notably, the Ras family members HRAS and RhoA are most likely not subjected to miR-
181a posttranscriptional regulation in SCC13 cells as demonstrated by transfectional miR-
181a modulation and gene expression analysis via qPCR and Western blotting (S12 Fig).
miR-181a mediates its tumor-suppressive role through KRAS signaling
via the MAPK pathway
Following the observation that miR-181a in keratinocytes correlated negatively with KRAS
expression and with cellular viability, we were interested in a functional role of KRAS in ker-
atinocytes. First we stably overexpressed KRAS in HaCaT using the pUNO KRAS plasmid
(HaCaT pUNO KRAS) and performed a WST-1 assay. The result revealed that KRAS, when
overexpressed, was able to boost viability in HaCaT similarly as a miR-181a knock down did.
Notably, MAPK signaling was activated during this process (Fig 4A). Aiming to address the
question whether there is a direct functional connection between miR-181a and KRAS we trans-
fected HaCaT kd miR-181a with siRNA against KRAS or control siRNA. As expected, HaCaT
cells harboring a stable miR-181a knock-down proliferated faster when only transfected with
miR-181a in cutaneous squamous cell carcinoma
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control siRNA, similarly as observed before. Reducing miR-181a’s target KRAS, using siRNA,
abolished this effect (Fig 4B). As mentioned before, MAPK signaling was activated as a result of
KRAS overexpression. Therefore, we speculated that KRAS uses the MAPK signaling pathway
to mediate its oncogenic signals in the cell. Initially, we treated HaCaT cells using epidermal
growth factor (EGF) to trigger MAPK signaling, resulting in enhanced proliferation rates simi-
larly as observed in HaCaT kd miR-181a (Fig 4C). Furthermore, we used HaCaT kd miR-181a
which exhibited increased viability compared to control. This difference was abolished upon
treatment with a MEK inhibitor (Fig 4D).
Suppression of KRAS by siRNA knock down, on the other hand, decreased viability in primary
patient-derived SCC cells (SCC) similarly as miR-181a overexpression did (Fig 4E). Additionally,
overexpressed KRAS rescued miR-181a mimics-induced effects in SCC13 to a large part (Fig 4F).
miR-181a levels increased during keratinocyte differentiation
Since SCC can be characterized by disturbed differentiation, we speculated that miR-181a
expression might be regulated during this process.
Fig 3. miR-181a targets KRAS directly. Cells were transfected with miRNA mimics (A) or inhibitors (C) for
48 hours or transduced with pLKO.miRNA.inhibitor / pLKO.miRNA (kd miR-181a / ki miR-181a) for stable
miRNA modulation (B and D). Cells were lysed and mRNA or protein level analyses were performed using
SYBR green qPCR or Western Blot respectively. (F) HaCaT cells were stably transfected with the indicated
pUNO KRAS over expression plasmids in selection medium. Selected clones were transfected with miR-181a
mimics for 48 hours following by WST-1 assay and Western Blot. (E) The panel in the left illustrates the three
main miR-181a binding sites in KRAS 3’UTR and the according mutations. Student’s t-Test was used to
calculate P values.
https://doi.org/10.1371/journal.pone.0185028.g003
miR-181a in cutaneous squamous cell carcinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0185028 September 20, 2017 9 / 16
First we differentiated primary healthy keratinocytes by keeping them cultured confluent
for a week. Direct cell-cell contact is required for Notch1 activation which subsequently initi-
ates the differentiation cascade. Comparing these matured cells with proliferating ones
revealed increased miR-181a levels accompanied by clearly elevated differentiation markers in
the differentiated subset (Figure A in S10 Fig). SCC13 cells which cannot differentiate due to
Notch1 defects, regained the ability to mature when Notch1 was inducibly knocked in. During
differentiation miR-181a levels went up (S10C Fig and S11 Fig). Induction of keratinocyte dif-
ferentiation by adding Ca2+ to the medium or by UVA irradiation lead to similar results (Fig-
ures B and D in S9 Fig).
Discussion
In our study we have identified miR-181a as a critical factor in SCC progression. The pub-
lished body of evidence on miR-181a mainly shows a carcinogenic role for miR-181a such as
in [16–19], making miR-181a a so-called ‘oncomir´. A smaller part of the data on miR-181a,
however, identifies miR-181a as a tumor suppressor in some cancers of the brain and the
hematopoietic lineage [20–22]. This tumor suppression seems mainly to impact invasion and
metastasis in tumors of the liver [23], salivary glands [24] and the ovary [25], and to a smaller
part to impact proliferation such as in non-small cell lung cancer (NSCLC) [26] and acute
myeloid leukemia [27]. These discrepancies on the function of miR-181a in different tumors,
highlight miR-181a’s context specificity depending on the environment. Our data show a
tumor-suppressive role of miR-181a in the context of keratinocyte cancer with an impact on
SCC proliferation. Contrary to miR-181a knockdown, reestablishing miR-181a levels in SCC
attenuates cancer both in vivo and in vitro. Showing functionality beyond epithelial cancers,
Fig 4. miR-181a mediates its tumor suppressive role through KRAS which signals via the MAPK
pathway. Cells were transfected with the indicated siRNAs or miRNA mimics (A). In addition to siRNA/mimics
the cells were transduced with the indicated plasmids (A—F). All transfections were carried out for 48 hours. A
subset of the cells was seeded into 96 well plates, followed by WST-1 assay, while RNA and protein was
isolated from the left overs. Protein and mRNA levels were determined by Western Blot or SYBR Green qPCR
respectively. Student’s t-Test was used to calculate P values. kd = knock down, SCC = cultured SCC cells
derived from patient samples.
https://doi.org/10.1371/journal.pone.0185028.g004
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miR181a overexpression suppresses cell growth in xenograft tumors in chronic myelogenous
leukemia [28] and large B-cell lymphoma [29]. The effect size on SCC in our study seems
larger, suggesting therapeutic potential for miR-181a against SCC.
Based on known interaction of miR181a with KRAS [30], our study identified a direct inter-
action of the proto-oncogene KRAS with miR-181a in SCC confirming findings from other
organ tumors [15, 26]. While this direct interaction has already been demonstrated using a
dual luciferase assay [15, 27], we document this interaction in our system in a novel fashion by
mutating the 3’-UTR of KRAS coupled with actual KRAS expression. This system allowed us to
perceive the miR-181a-KRAS interaction above the background of endogenous KRAS expres-
sion. We thus support the previously found interaction between miR-181a and KRAS 3’UTR
and directly link its main functional consequence to SCC, namely a change in cellular viability.
Furthermore, the protein levels of Ras family members HRAS and RhoA were not affected by
miR-181a modulation further underlining KRAS as miR-181a’s functional target in SCC. The
mechanism of KRAS in keratinocytes, however, is only sketchily described. Our data confirm
that the well-known downstream mediators of KRAS function are found in the MAP kinase
pathway [24, 31]. While KRAS acts as an oncogenic driver mainly by activating mutations [32–
34], posttranscriptional control of KRAS by miRNA deregulation has been identified repeat-
edly [35–38]. Our data suggest that such posttranscriptional control of KRAS by miR-181a
may be critical in SCC development.
Differentiation is a key mechanism in cell control, maintaining homeostasis and preventing
cancer development [39, 40]. Our data shows that differentiation in keratinocytes at large
increases miR-181a expression, suggesting a role for miR-181a in a common pathway of differ-
entiation, and that removing miR-181a is critical for the transition of keratinocytes into SCC.
A similar weight has been reported in keratinocytes for miR-203 and miR-24 [41–43], under-
lining the impact of miRNAs in differentiation [44–46]. We thus believe that miR-181a is an
important mediator of differentiation in keratinocytes. In summary, our data singles out miR-
181a as a critical determinant in keratinocyte differentiation and control of SCC development.
Manipulating miR-181a in vivo demonstrates the potential of miR-181a as a potential thera-
peutic miRNA in SCC.
Supporting information
S1 Fig. Endogenous miR-181a levels of cell lines used in the present study. Total RNA was
isolated and transcribed into cDNA. miR-181a levels of various cell lines were determined via
TaqMan qPCR. PK = cultured healthy keratinocytes derived from patient samples, SCC = SCC
cells derived from patient samples.
(TIF)
S2 Fig. Genotyping of H-, K-, and NRAS codons 12, 13, and 61 mutations in keratinocyte
cell lines. The used cell lines, HaCaT and SCC-13, were assessed for their mutation status in
the activating codons (red arrows) of the HRAS (A+B), KRAS (C+D) and NRAS (E+F) genes.
Genomic DNA was isolated and regions of interest were amplified using PCR. Products were
gel purified and prepared for Sanger sequencing.
(TIF)
S3 Fig. WST-1 viability assay represents keratinocyte proliferation rates. Primary keratino-
cytes and HaCaT cells were transfected with miR-181a inhibitors or control sequence and
seeded into Petri dishes. Cells were incubated for 96 hours and manually counted at the experi-
ment’s end point. WST-1 and BrdU assays were performed in 96 well plates after 96 hours of
incubation time. Statistical analysis was performed using Student’s t-Test. PK = cultured
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healthy keratinocytes derived from patient samples.
(TIF)
S4 Fig. miR-181a knock down promotes cyst formation in vivo. (A) HaCaT knock down
(kd) miR-181a cells were injected subcutaneously into nude mice. Arrows in the upper panels
highlight cysts or rudimental cysts. Lower panels show H&E stainings of the cysts. Length of
black bars = 1mm, Length of green bars = 30 μm. (B) Cyst volumes at the experiment’s end
point (day 24). (C) miR-181a levels of cysts isolated after mice were terminated. Whole RNA
was isolated and transcribed into cDNA followed by TaqMan qPCR. Statistics were performed
using Student’s t-Test and Welch’s correction. kd = knock down.
(TIF)
S5 Fig. miR-181a levels of HaCaT cells harboring stable miR-181a knock down. Whole
RNA was isolated and transcribed into cDNA. miR-181a levels of HaCaT kd miR-181a were
determined via TaqMan qPCR. Statistics were performed using Student’s t-Test. kd = knock
down.
(TIF)
S6 Fig. Up regulation of miR-181a leads to decreased tumor growth in vivo. (A) SCC13
Tet-ON miR-181a were injected subcutaneously into nude mice. Doxycycline (200 mg/kg)
was administered via food pellets. (B) Tumor volumes at the statistical endpoint of the experi-
ment (day 21). (C) Kaplan-Meier survival curve. (D) miR-181a levels of tumors isolated after
mice were terminated. Whole RNA was isolated and transcribed into cDNA follow by TaqMan
qPCR. Statistics were performed using Student’s t-Test and Welch’s correction.
(TIF)
S7 Fig. miR-181a levels of SCC13 with artificial miR-181a up regulation. (A) SCC13 Tet-
On miR-181a were incubated with 500nM doxycycline for 48 hours. (B) SCC13 stably over
expressing miR-181a. Whole RNA was isolated and transcribed into cDNA followed by Taq-
Man qPCR. Statistics were performed using Student’s t-Test. ki = knock in.
(TIF)
S8 Fig. miR-181a up regulation induces apoptosis in SCC13. (A) SCC13 cells were trans-
fected with miR-181a mimics for 48 hours. One fraction was stained for 7AAD and AnnexinV
following FACS analysis. Cells were irradiated with 0.06 J/cm2 UVB for gating setup and
served as a positive control. Protein from the other fraction was isolated and used for cleaved
caspase 3 determination via Western blotting. (B). Cells were transfected with miR-181a mim-
ics for 48 hours and seeded into petri dishes. 96 hours post transfection pictures were taken.
Length of black bars = 150μm.
(TIF)
S9 Fig. miR-181a targets KRAS directly. Indicated pUNO KRAS over expression plasmids
and miR-181a mimics were transfected simultaneously into HEK293T cells for 48 hours. Pro-
tein was extracted followed by Western Blot. The panel in the left illustrates the three main
miR-181a binding sites in KRAS 3’UTR and the according mutations.
(TIF)
S10 Fig. miR-181a levels are increased during keratinocyte differentiation. Cells were dif-
ferentiated by keeping them in a confluent state for a week (A), by Ca2+ exposure (B), by trans-
ducing an inducible Notch1 plasmid (C) or by exposing them to 25 joule UVA irradiation.
Protein and mRNA levels were determined by Western Blot or qPCR respectively. Student’s t-
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Test was used to calculate P values.
(TIF)
S11 Fig. SCC13 cells harboring a tetracycline inducible Notch1 construct. SCC13 pIND20
Notch1 were incubated with 500nM doxycycline for 48 hours. Whole RNA was isolated and
transcribed into cDNA followed by TaqMan qPCR. qPCR primers were designed to target the
expression sequence (intra-cellular domain of Notch1) of pIND20 Notch1.
(TIF)
S12 Fig. miR-181a modulation does not lead to changes in mRNA/protein levels of Ras
family members HRAS and RhoA. Cells were transfected with miRNA inhibitors (A) or
mimics (B) for 48 hours. Cells were lysed and protein level analyses were performed using
Western Blot. Total RNA extracts were used for oligo dT cDNA synthesis followed by SYBR
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